Tearsheet

Abbott Laboratories (ABT)

Market Price (9/16/2025): $131.4 | Market Cap: $229.1 Bil
Sector: Health Care | Industry: Health Care Equipment

Abbott Laboratories (ABT)

Market Price (9/16/2025): $131.4
Market Cap: $229.1 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.3%	Weak multi-year price returns 2Y Excs Rtn is -14%, 3Y Excs Rtn is -35%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 27x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%, CFO LTM is 9.0 Bil, FCF LTM is 6.8 Bil		Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5%
2	Low stock price volatility Vol 12M is 22%

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.3%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%, CFO LTM is 9.0 Bil, FCF LTM is 6.8 Bil
2	Low stock price volatility Vol 12M is 22%
3	Weak multi-year price returns 2Y Excs Rtn is -14%, 3Y Excs Rtn is -35%
4	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 27x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x
5	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5%

Market Valuation

	9/16/25	2024	2023	2022	2021
Share Price CYE	$131.40	$111.50	$106.38	$104.03	$131.15
Market Cap CYE ($ Bil)	229.1	193.7	185.0	181.4	232.1
Total Debt ($ Bil)	13.4	15.0	15.6	17.7	19.0
Total Cash ($ Bil)	7.3	8.0	7.3	10.2	10.2
Enterprise Value ($ Bil)	235.2	208.7	200.6	199.1	251.1
Valuation Ratios
P/S TTM	5.3	4.7	4.8	4.4	5.8
P/EBIT TTM	27.2	26.0	26.2	21.7	28.6
P/E TTM	16.4	14.7	33.5	27.8	35.3
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.9
P/E TTM (Sector)	-1.9	-1.6	-1.5	-1.4	-2.9

	9/16/25	2024	2023
Share Price CYE	$131.40	$111.50	$106.38
Market Cap CYE ($ Bil)	229.1	193.7	185.0
Total Debt ($ Bil)	13.4	15.0	15.6
Total Cash ($ Bil)	7.3	8.0	7.3
Enterprise Value ($ Bil)	235.2	208.7	200.6
Valuation Ratios
P/S TTM	5.3	4.7	4.8
P/EBIT TTM	27.2	26.0	26.2
P/E TTM	16.4	14.7	33.5
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-1.9	-1.6	-1.5

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ABT Return	28%	31%	-21%	2%	5%	18%	70%
Peers Return	12%	15%	-13%	3%	-2%	7%	22%
S&P 500 Return	16%	27%	-19%	24%	23%	12%	104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: JNJ, BSX, MDT, DXCM, BAX. See ABT Returns vs. Peers.
[3] 2025 data is for the year up to 9/15/2025 (YTD)

Interactive Breakdown

Abbott Laboratories Interactive Breakdown Analysis

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Abbott Laboratories Earnings Notes
2	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From BDX, RMD	Actionable
3	Abbott Laboratories vs Microsoft: Which Is A Better Investment?	Counter-Intuitive Comparisons
4	Abbott Laboratories vs Eli Lilly: Which Is A Better Investment?	Counter-Intuitive Comparisons
5	Abbott Laboratories vs Stryker: Which Is A Better Investment?	Counter-Intuitive Comparisons
6	How Does ABT Stack Up Against Its Peers?	Peer Comparison
7	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From LLY, COR
8	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From RMD, GMED
9	Day 6 of Gains Streak for Abbott Laboratories Stock with 6.4% Return (vs. 20% YTD) [8/8/2025]	Notification
10	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From GMED, ITGR, RMD, UFPT	Actionable
11	ARTICLES
12	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX		September 9th, 2025
13	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX		August 27th, 2025
14	ABT Stock Up 6.4% after 6-Day Win Streak		August 9th, 2025
15	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From GMED, RMD		August 8th, 2025
16	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From GMED, RMD		July 29th, 2025

	Title
0	DASHBOARDS
1	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
2	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
3	ABT Stock Up 6.4% after 6-Day Win Streak
4	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From GMED, RMD
5	Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From GMED, RMD
6	ARTICLES
7	Abbott Laboratories Earnings Notes
8	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From BDX, RMD
9	Abbott Laboratories vs Microsoft: Which Is A Better Investment?
10	Abbott Laboratories vs Eli Lilly: Which Is A Better Investment?
11	Abbott Laboratories vs Stryker: Which Is A Better Investment?
12	How Does ABT Stack Up Against Its Peers?
13	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From LLY, COR
14	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From RMD, GMED
15	Day 6 of Gains Streak for Abbott Laboratories Stock with 6.4% Return (vs. 20% YTD) [8/8/2025]
16	Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From GMED, ITGR, RMD, UFPT

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	NXTT	Next Technology	18947.6%	1080.3%
2	VCIG	VCI Global	2528.6%	-66.8%
3	BDSX	Biodesix	1926.1%	-75.2%
4	CLSD	Clearside Biomedical	1136.3%	-72.3%
5	SDOT	Sadot	1033.9%	-78.2%
6	CHEK	Check-Cap	184.2%	114.2%
7	ATCH	AtlasClear	153.8%	-89.7%
8	HSDT	Helius Medical Technologies	141.7%	-96.4%
9	MTVA	MetaVia	115.5%	-26.1%
10	IHT	InnSuites Hospitality Trust	66.0%	54.9%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ATYR	aTyr Pharma	-83.2%	-72.0%
2	NAKA	Kindly MD	-55.4%
3	REX	REX American Resources	-49.8%	-26.7%
4	FAAS	DigiAsia	-39.2%	-83.2%
5	EVTV	Envirotech Vehicles	-32.8%	-77.4%
6	WLDS	Wearable Devices	-30.0%	-24.4%
7	ZONE	CleanCore Solutions	-29.5%	107.8%
8	CGTX	Cognition Therapeutics	-29.0%	119.6%
9	SIDU	Sidus Space	-28.7%	-80.8%
10	BNGO	Bionano Genomics	-28.6%	-84.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	NXTT	Next Technology	18985.5%	1080.3%
2	BDSX	Biodesix	1658.4%	-75.2%
3	VCIG	VCI Global	1460.0%	-66.8%
4	CLSD	Clearside Biomedical	1075.2%	-72.3%
5	SDOT	Sadot	806.7%	-78.2%
6	WLDS	Wearable Devices	539.8%	-24.4%
7	QMMM	QMMM	536.6%	5505.5%
8	ATCH	AtlasClear	382.9%	-89.7%
9	OPI	Office Properties Income Trust	274.5%	-8.3%
10	CWD	CaliberCos	246.5%	-46.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	DGNX	Diginex	-83.7%
2	ATYR	aTyr Pharma	-81.4%	-72.0%
3	LGCL	Lucas GC	-73.2%	-78.3%
4	NAKA	Kindly MD	-72.8%
5	OCTO	Eightco	-67.8%	562.1%
6	YYGH	YY	-67.0%	-78.2%
7	SNTG	Sentage	-58.1%	57.5%
8	REX	REX American Resources	-50.7%	-26.7%
9	BINI	Bollinger Innovations	-49.2%	-100.0%
10	SLXN	Silexion Therapeutics	-49.2%	-88.0%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	11963.5%	11963.5%
2	GIBO	GIBO	7309.3%
3	CHSN	Chanson International	5551.3%	-99.3%
4	LNZA	LanzaTech Global	5145.9%	-85.7%
5	QMMM	QMMM	2490.3%	5505.5%
6	NXTT	Next Technology	2167.7%	1080.3%
7	VTAK	Catheter Precision	1543.9%	-70.5%
8	CURX	Curanex Pharmaceuticals	1282.0%	1282.0%
9	VCIG	VCI Global	1278.3%	-66.8%
10	OCTO	Eightco	800.6%	562.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	CJET	Chijet Motor	-93.3%	-95.1%
2	ELPW	Elong Power	-92.4%	-76.5%
3	STFS	Star Fashion Culture	-92.1%	-97.9%
4	ETS	Elite Express	-92.0%	-92.0%
5	NAKA	Kindly MD	-91.7%
6	BINI	Bollinger Innovations	-90.5%	-100.0%
7	FLYE	Fly-E	-89.8%	-81.2%
8	JEM	707 Cayman	-89.8%	-98.3%
9	NUTR	NusaTrip	-86.7%	-86.7%
10	CUPR	Cuprina	-84.9%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	NXTT	Next Technology	18947.6%	1080.3%
2	VCIG	VCI Global	2528.6%	-66.8%
3	BDSX	Biodesix	1926.1%	-75.2%
4	CLSD	Clearside Biomedical	1136.3%	-72.3%
5	SDOT	Sadot	1033.9%	-78.2%
6	CHEK	Check-Cap	184.2%	114.2%
7	ATCH	AtlasClear	153.8%	-89.7%
8	HSDT	Helius Medical Technologies	141.7%	-96.4%
9	MTVA	MetaVia	115.5%	-26.1%
10	IHT	InnSuites Hospitality Trust	66.0%	54.9%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ATYR	aTyr Pharma	-83.2%	-72.0%
2	NAKA	Kindly MD	-55.4%
3	REX	REX American Resources	-49.8%	-26.7%
4	FAAS	DigiAsia	-39.2%	-83.2%
5	EVTV	Envirotech Vehicles	-32.8%	-77.4%
6	WLDS	Wearable Devices	-30.0%	-24.4%
7	ZONE	CleanCore Solutions	-29.5%	107.8%
8	CGTX	Cognition Therapeutics	-29.0%	119.6%
9	SIDU	Sidus Space	-28.7%	-80.8%
10	BNGO	Bionano Genomics	-28.6%	-84.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	NXTT	Next Technology	18985.5%	1080.3%
2	BDSX	Biodesix	1658.4%	-75.2%
3	VCIG	VCI Global	1460.0%	-66.8%
4	CLSD	Clearside Biomedical	1075.2%	-72.3%
5	SDOT	Sadot	806.7%	-78.2%
6	WLDS	Wearable Devices	539.8%	-24.4%
7	QMMM	QMMM	536.6%	5505.5%
8	ATCH	AtlasClear	382.9%	-89.7%
9	OPI	Office Properties Income Trust	274.5%	-8.3%
10	CWD	CaliberCos	246.5%	-46.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	DGNX	Diginex	-83.7%
2	ATYR	aTyr Pharma	-81.4%	-72.0%
3	LGCL	Lucas GC	-73.2%	-78.3%
4	NAKA	Kindly MD	-72.8%
5	OCTO	Eightco	-67.8%	562.1%
6	YYGH	YY	-67.0%	-78.2%
7	SNTG	Sentage	-58.1%	57.5%
8	REX	REX American Resources	-50.7%	-26.7%
9	BINI	Bollinger Innovations	-49.2%	-100.0%
10	SLXN	Silexion Therapeutics	-49.2%	-88.0%

Peer Comparisons for Abbott Laboratories

Financials

	ABT	JNJ	BSX	MDT	DXCM	BAX	Median
Name	Abbott L.	Johnson .	Boston S.	Medtronic	DexCom	Baxter I.
Mkt Price	131.33	177.40	99.87	93.43	75.58	23.80	96.65
Mkt Cap	229.0	426.9	147.8	119.7	29.6	12.2	133.8
Rev LTM	43,109	90,627	18,494	34,200	4,301	10,887	26,347
Op Inc LTM	7,515	22,228	3,388	6,647	687	398	5,018
FCF LTM	6,775	16,397	3,234	5,303	571	218	4,268
FCF 3Y Avg	5,972	16,926	2,114	4,964	567	658	3,539
CFO LTM	9,037	23,028	4,285	7,146	988	765	5,716
CFO 3Y Avg	8,130	22,248	3,014	6,625	884	1,166	4,820

Growth & Margins

	ABT	JNJ	BSX	MDT	DXCM	BAX	Median
Name	Abbott L.	Johnson .	Boston S.	Medtronic	DexCom	Baxter I.
Rev Chg LTM	5.9%	4.7%	21.4%	5.0%	9.3%	3.6%	5.4%
Rev Chg 3Y Avg	-1.5%	4.0%	14.6%	3.3%	17.3%	-5.7%	3.6%
Rev Chg Q	7.4%	5.8%	22.8%	8.4%	15.2%	4.3%	7.9%
QoQ Delta Rev Chg LTM	1.8%	1.5%	5.4%	2.0%	3.7%	1.1%	1.9%
Op Mgn LTM	17.4%	24.5%	18.3%	19.4%	16.0%	3.7%	17.9%
Op Mgn 3Y Avg	16.2%	26.3%	17.6%	18.6%	15.8%	2.9%	16.9%
QoQ Delta Op Mgn LTM	0.6%	-0.2%	-0.2%	-0.1%	0.7%	0.1%	0.0%
CFO/Rev LTM	21.0%	25.4%	23.2%	20.9%	23.0%	7.0%	22.0%
CFO/Rev 3Y Avg	19.6%	25.7%	18.8%	20.2%	23.2%	11.2%	19.9%
FCF/Rev LTM	15.7%	18.1%	17.5%	15.5%	13.3%	2.0%	15.6%
FCF/Rev 3Y Avg	14.4%	19.6%	13.1%	15.1%	14.9%	6.3%	14.7%

Valuation

	ABT	JNJ	BSX	MDT	DXCM	BAX	Median
Name	Abbott L.	Johnson .	Boston S.	Medtronic	DexCom	Baxter I.
Mkt Cap	229.0	426.9	147.8	119.7	29.6	12.2	133.8
P/S	5.3	4.7	8.0	3.5	6.9	1.1	5.0
P/EBIT	27.2	15.1	44.4	18.7	36.9	381.5	32.0
P/E	16.4	18.8	59.0	25.7	51.9	-78.8	22.3
P/CFO	25.3	18.5	34.5	16.8	30.0	16.0	21.9
Total Yield	7.8%	8.1%	1.7%	6.9%	1.9%	2.6%	4.7%
Dividend Yield	1.7%	2.8%	0.0%	3.0%	0.0%	3.8%	2.3%
FCF Yield 3Y Avg	3.0%	4.5%	1.8%	4.5%	1.4%	3.5%	3.2%
D/E	0.1	0.1	0.1	0.2	0.1	0.8	0.1
Net D/E	0.0	0.1	0.1	0.2	-0.0	0.7	0.1

Returns

	ABT	JNJ	BSX	MDT	DXCM	BAX	Median
Name	Abbott L.	Johnson .	Boston S.	Medtronic	DexCom	Baxter I.
1M Rtn	-0.3%	1.2%	-3.2%	0.4%	-6.6%	-0.9%	-0.6%
3M Rtn	-1.6%	15.1%	-1.6%	7.1%	-8.9%	-22.2%	-1.6%
6M Rtn	3.8%	10.7%	1.0%	1.7%	5.9%	-30.8%	2.8%
12M Rtn	15.0%	10.6%	19.9%	7.3%	8.7%	-38.7%	9.7%
3Y Rtn	33.9%	16.0%	139.5%	14.4%	-16.1%	-55.7%	15.2%
1M Excs Rtn	-0.7%	0.0%	-6.4%	-0.7%	-7.7%	-4.2%	-2.5%
3M Excs Rtn	-13.4%	3.1%	-10.5%	-2.7%	-18.5%	-32.4%	-12.0%
6M Excs Rtn	-12.7%	-6.6%	-14.5%	-15.3%	-10.4%	-47.6%	-13.6%
12M Excs Rtn	-4.3%	-8.0%	1.3%	-12.3%	-8.7%	-57.1%	-8.4%
3Y Excs Rtn	-35.0%	-47.6%	68.7%	-47.7%	-82.6%	-121.2%	-47.6%

Comparison Analyses

	Title
0	How Does ABT Stack Up Against Its Peers?
1	AMGN Could Deliver 31% Returns And Outperform ABT
2	ABT or TMO - With 9.0% Return Forecast, TMO Probably Deserves Your Money
3	Why ISRG With 47% Upside May Beat ABT?
4	With 11% Gains On The Table, MDT May Outshine ABT
5	BSX Could Deliver 39% Returns And Outperform ABT
6	Why JNJ With 12% Upside May Beat ABT?
7	ABT or BAX - With 18% Return Forecast, BAX Probably Deserves Your Money
8	Why DXCM With 65% Upside May Beat ABT?
9	Abbott Laboratories vs. Herbalife: Both Seem Similar Bets

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		2/21/2025	2/16/2024	2/17/2023	2/18/2022	2/19/2021	2/21/2020
Key Financials
Total Revenue	43,109	41,950	40,109	43,653	43,075	34,608	31,904
Ebitda	11,569	10,790	10,544	12,131	12,282	8,841	7,761
Operating Income	7,515	6,825	6,478	8,362	8,425	5,357	4,532
Net Income	13,979	13,402	5,723	6,933	7,071	4,495	3,687
EPS	8.05	7.67	3.28	3.94	3.97	2.52	2.07
Growth Rates
Total Revenue Growth	5.9%	4.6%	-8.1%	1.3%	24.5%	8.5%	4.3%
EBITDA Growth	11.6%	2.3%	-13.1%	-1.2%	38.9%	13.9%	11.2%
Operating Income Growth	15.9%	5.4%	-22.5%	-0.7%	57.3%	18.2%	24.2%
Net Income Growth	151.6%	134.2%	-17.5%	-2.0%	57.3%	21.9%	55.7%
Margins
EBITDA Margin	26.8%	25.7%	26.3%	27.8%	28.5%	25.5%	24.3%
Operating Income Margin	17.4%	16.3%	16.2%	19.2%	19.6%	15.5%	14.2%
Net Income Margin	32.4%	31.9%	14.3%	15.9%	16.4%	13.0%	11.6%
Cash & Debt
Total Cash	7,282	7,967	7,279	10,170	10,249	7,148	4,140
Total Debt	13,437	15,021	15,628	17,716	19,006	19,649	18,894
Net Debt / (Cash)	6,155	7,054	8,349	7,546	8,757	12,501	14,754
Cash Flows
Net Cash from Operations	9,037	8,558	7,261	9,581	10,533	7,901	6,136
Free Cash from Operations	6,775	6,351	5,059	7,804	8,648	5,724	4,498
Returns to Shareholders
Dividends	3,973	3,836	3,556	3,309	3,202	2,560	2,270
Share Repurchases	1,352	1,295	1,227	3,795	2,299	403	718

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	7/30/2025	4/30/2025	2/21/2025	10/31/2024	7/31/2024	5/2/2024	2/16/2024	11/1/2023	8/3/2023	5/4/2023	2/17/2023	11/1/2022
Key Financials Quarterly
Total Revenue	11,142	10,358	10,974	10,635	10,377	9,964	10,241	10,143	9,978	9,747	10,091	10,410
Ebitda	3,048	2,665	2,973	2,883	2,552	2,382	2,767	2,661	2,595	2,521	2,281	2,714
Operating Income	2,052	1,693	1,911	1,859	1,669	1,386	1,780	1,647	1,542	1,509	1,304	1,770
Net Income	1,779	1,325	9,229	1,646	1,302	1,225	1,594	1,436	1,375	1,318	1,033	1,435
EPS	1.02	0.76	5.33	0.94	0.74	0.70	0.92	0.82	0.79	0.75	0.59	0.82
Key Financials TTM
Total Revenue TTM	43,109	42,344	41,950	41,217	40,725	40,326	40,109	39,959	40,226	41,505	43,653	45,030
Ebitda TTM	11,569	11,073	10,790	10,584	10,362	10,405	10,544	10,058	10,111	10,822	12,131	13,191
Operating Income TTM	7,515	7,132	6,825	6,694	6,482	6,355	6,478	6,002	6,125	6,959	8,362	9,436
Net Income TTM	13,979	13,502	13,402	5,767	5,557	5,630	5,723	5,162	5,161	5,804	6,933	7,889
Growth Rates Quarterly
Total Revenue Growth	7.4%	4.0%	7.2%	4.9%	4.0%	2.2%	1.5%	-2.6%	-11.4%	-18.1%	-12.0%	-4.7%
EBITDA Growth	19.4%	11.9%	7.4%	8.3%	-1.7%	-5.5%	21.3%	-2.0%	-21.5%	-34.2%	-31.7%	-21.9%
Operating Income Growth	22.9%	22.2%	7.4%	12.9%	8.2%	-8.2%	36.5%	-6.9%	-35.1%	-48.2%	-45.2%	-30.5%
Net Income Growth	36.6%	8.2%	479.0%	14.6%	-5.3%	-7.1%	54.3%	0.1%	-31.9%	-46.1%	-48.1%	-31.7%
Margins Quarterly
EBITDA Margin	27.4%	25.7%	27.1%	27.1%	24.6%	23.9%	27.0%	26.2%	26.0%	25.9%	22.6%	26.1%
Operating Income Margin	18.4%	16.3%	17.4%	17.5%	16.1%	13.9%	17.4%	16.2%	15.5%	15.5%	12.9%	17.0%
Net Income Margin	16.0%	12.8%	84.1%	15.5%	12.5%	12.3%	15.6%	14.2%	13.8%	13.5%	10.2%	13.8%
Cash & Debt
Total Cash	7,282	6,844	7,967	7,788	7,219	6,651	7,279	7,047	8,155	9,532	10,170	9,907
Total Debt	13,437	13,242	15,021	14,979	14,754	14,586	15,628	15,528	16,846	16,900	17,716	16,414
Net Debt / (Cash)	6,155	6,398	7,054	7,191	7,535	7,935	8,349	8,481	8,691	7,368	7,546	6,507
Cash Flows Quarterly
FCF from Operations	2,047	1,417	2,868	2,705	1,960	1,025	3,038	1,877	1,203	1,143	2,326	2,780
Cash Flows TTM
FCF from Operations TTM	9,037	8,950	8,558	8,728	7,900	7,143	7,261	6,549	7,452	8,659	9,581	10,322
Returns to Shareholders Quarterly
Dividends	1,029	1,026	958	960	961	957	888	888	890	890	823	826
Share Repurchases	6	280	315	751	3	226	259	2	426	540	685	798
Return on Invested Capital (ROIC) Quarterly
ROIC	110.3%	78.9%	108.4%	87.7%	71.8%	59.6%	75.7%	66.8%	59.6%	69.1%	54.1%	88.8%
Return on Invested Capital (ROIC) TTM
ROIC TTM	122.1%	111.5%	96.8%	79.2%	73.4%	69.0%	66.6%	59.0%	58.0%	78.4%	92.5%	122.8%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Medical Devices	16,887	14,802	14,485	11,787	12,239
Diagnostics	9,988	16,469	15,526	10,805	7,713
Nutritionals	8,154	7,459	8,294	7,647	7,409
Established Pharmaceutical	5,066	4,912	4,718	4,303	4,486
Other	14	11	52	66	57
Total	40,109	43,653	43,075	34,608	31,904

Operating Income by Segment

$ Mil	2024	2023	2022	2021	2020
Medical Devices	5,306	4,436	4,533	3,038	3,769
Diagnostics	2,433	6,640	6,237	3,725	1,912
Nutritionals	1,333	706	1,763	1,751	1,705
Established Pharmaceutical	1,206	1,049	889	794	904
Total	10,278	12,831	13,422	9,308	8,290

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
Goodwill and intangible assets	32,494			38,528	40,220
Medical Devices	9,029	7,844	7,261	6,893	6,640
All other	8,458			5,096	4,637
Cash and investments	8,078			7,969	5,023
Diagnostics	7,767	7,985	7,699	7,696	5,235
Nutritionals	4,270	3,625	3,425	3,478	3,274
Established Pharmaceutical	3,118	2,883	2,789	2,888	2,858
Total	73,214	22,337	21,174	72,548	67,887

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$131.33
Market Cap ($ Bil)	229.0
First Trading Date	04/06/1983
Distance from 52W High	-5.5%
	50 Days	200 Days
DMA Price	$130.36	$127.26
DMA Trend	up	indeterminate
Distance from DMA	0.7%	3.2%
	3M	1YR
Volatility	25.3%	22.0%
Downside Capture	-0.09	0.14
Upside Capture	-22.92	29.21
Correlation (SPY)	4.3%	22.9%

ABT Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.11	-0.20	0.01	0.27	0.24	0.44
Up Beta	1.09	0.46	0.55	0.22	0.18	0.49
Down Beta	-0.76	-0.29	0.08	0.49	0.34	0.47
Up Capture	33%	-50%	-18%	8%	22%	13%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	11	23	35	67	135	388
Down Capture	-55%	-56%	-36%	23%	23%	67%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	10	19	28	59	114	362

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8292025
Short Interest: Shares Quantity	17,753,634
Short Interest: % Change Since 8152025	3.8%
Average Daily Volume	4,507,472
Days-to-Cover Short Interest	3.94
Basic Shares Quantity	1,743,437,000
Short % of Basic Shares	1.0%

Returns Analyses

	Title
0	Will You Be Comfortable Buying Abbott Laboratories Stock?
1	ABT YTD Stock Return Of 19% Outperforms BAX by 15% and Outperforms BSX by 4.0%
2	Will You Be Comfortable Buying Abbott Laboratories Stock?
3	Abbott Laboratories During 2008 Recession vs. 2022 Inflation Shock: ABT Stock Has Recovered To Its December 2021 High And Looks Fairly Priced
4	ABT YTD Stock Return Of 3.8% Outperforms BAX by 16% and Outperforms MDT by 0.08%
5	Abbott Laboratories Stock Return Comparison
6	Abbott Laboratories Total Shareholder Return (TSR): 2.1% in 2023 and 1.8% 3-yr returns (below peer average)

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
7/17/2025	-8.5%	-4.5%	-1.9%
4/16/2025	2.8%	2.9%	5.6%
1/22/2025	0.8%	9.1%	14.0%
10/16/2024	1.5%	0.1%	-0.3%
7/18/2024	-4.4%	2.5%	6.0%
4/17/2024	-3.0%	-1.5%	-4.2%
1/24/2024	-2.8%	-0.5%	4.4%
10/18/2023	3.7%	2.9%	6.4%
...
SUMMARY STATS
# Positive	10	14	14
# Negative	14	10	10
Median Positive	3.0%	3.4%	5.1%
Median Negative	-2.4%	-1.7%	-2.9%
Max Positive	7.8%	9.1%	14.0%
Max Negative	-8.5%	-6.7%	-8.9%

	Forward Returns
7/17/2025	-8.5%	-4.5%	-1.9%
4/16/2025	2.8%	2.9%	5.6%
1/22/2025	0.8%	9.1%	14.0%
10/16/2024	1.5%	0.1%	-0.3%
7/18/2024	-4.4%	2.5%	6.0%
4/17/2024	-3.0%	-1.5%	-4.2%
1/24/2024	-2.8%	-0.5%	4.4%
10/18/2023	3.7%	2.9%	6.4%
7/20/2023	4.2%	6.3%	-2.2%
4/19/2023	7.8%	5.6%	4.5%
1/25/2023	-1.4%	-1.8%	-8.9%
10/19/2022	-6.5%	-6.7%	-1.3%
7/20/2022	-1.5%	-0.8%	0.6%
4/20/2022	2.2%	-2.5%	-6.0%
1/26/2022	-2.6%	3.2%	-3.7%
10/20/2021	3.3%	7.4%	7.8%
7/22/2021	-0.6%	1.3%	5.7%
4/20/2021	-3.6%	-1.6%	-6.1%
1/27/2021	-0.4%	4.8%	6.0%
10/21/2020	-2.2%	0.2%	1.3%
7/16/2020	-0.3%	3.6%	4.5%
4/16/2020	5.6%	5.0%	0.9%
1/22/2020	2.4%	-0.2%	-1.4%
10/16/2019	-0.2%	-1.8%	2.7%
SUMMARY STATS
# Positive	10	14	14
# Negative	14	10	10
Median Positive	3.0%	3.4%	5.1%
Median Negative	-2.4%	-1.7%	-2.9%
Max Positive	7.8%	9.1%	14.0%
Max Negative	-8.5%	-6.7%	-8.9%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	7302025	10-Q 6/30/2025
3312025	4302025	10-Q 3/31/2025
12312024	2212025	10-K 12/31/2024
9302024	10312024	10-Q 9/30/2024
6302024	7312024	10-Q 6/30/2024
3312024	5022024	10-Q 3/31/2024
12312023	2162024	10-K 12/31/2023
9302023	11012023	10-Q 9/30/2023
6302023	8032023	10-Q 6/30/2023
3312023	5042023	10-Q 3/31/2023
12312022	2172023	10-K 12/31/2022
9302022	11012022	10-Q 9/30/2022
6302022	8022022	10-Q 6/30/2022
3312022	5032022	10-Q 3/31/2022
12312021	2182022	10-K 12/31/2021
9302021	11032021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Boudreau Philip P	EVP AND CFO	8112025	Sell	134.55	5,550	746,758	6,862,505	Form
1	Blount Sally E.		5022025	Sell	129.66	2,600	337,116	4,415,960	Form
2	Shroff Eric	Senior Vice President	3042025	Sell	138.17	562	77,652	4,417,295	Form
3	Morrone Louis H.	EXECUTIVE VICE PRESIDENT	1302025	Sell	127.39	2,644	336,819		Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Abbott Laboratories (ABT)

Market Price (9/16/2025): $131.4 | Market Cap: $229.1 BilSector: Health Care | Industry: Health Care Equipment

Abbott Laboratories (ABT)

Market Price (9/16/2025): $131.4Market Cap: $229.1 BilSector: Health CareIndustry: Health Care Equipment

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Abbott Laboratories (ABT)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Abbott Laboratories

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/16/2025): $131.4 | Market Cap: $229.1 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (9/16/2025): $131.4
Market Cap: $229.1 Bil
Sector: Health Care
Industry: Health Care Equipment